StockNews.com Begins Coverage on Chimerix (NASDAQ:CMRX)

Stock analysts at StockNews.com started coverage on shares of Chimerix (NASDAQ:CMRX) in a note issued to investors on Tuesday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

A number of other brokerages have also commented on CMRX. Wedbush reaffirmed a “neutral” rating and issued a $8.55 price target (up previously from $7.00) on shares of Chimerix in a research note on Wednesday, March 5th. HC Wainwright reaffirmed a “neutral” rating and issued a $8.55 target price (down from $11.00) on shares of Chimerix in a research report on Wednesday, March 5th. Finally, Jefferies Financial Group reiterated a “hold” rating and set a $8.50 price target (down previously from $10.00) on shares of Chimerix in a research report on Wednesday, March 5th.

Chimerix Trading Up 0.2 %

CMRX stock opened at $8.53 on Tuesday. The stock has a market capitalization of $800.15 million, a price-to-earnings ratio of -9.07 and a beta of -0.17. The firm’s 50-day moving average price is $6.76 and its two-hundred day moving average price is $3.62. Chimerix has a 12-month low of $0.75 and a 12-month high of $8.54.

Chimerix (NASDAQ:CMRX) last announced its quarterly earnings results on Friday, March 21st. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.01. The business had revenue of $0.06 million for the quarter, compared to analysts’ expectations of $0.31 million. Equities analysts predict that Chimerix will post -0.99 EPS for the current year.

Insiders Place Their Bets

In other Chimerix news, CEO Michael T. Andriole sold 7,370 shares of Chimerix stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $4.52, for a total value of $33,312.40. Following the completion of the sale, the chief executive officer now owns 609,603 shares of the company’s stock, valued at approximately $2,755,405.56. This trade represents a 1.19 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last ninety days, insiders sold 20,760 shares of company stock valued at $91,175. Insiders own 13.10% of the company’s stock.

Institutional Investors Weigh In On Chimerix

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Deerfield Management Company L.P. Series C purchased a new stake in Chimerix during the fourth quarter valued at $13,124,000. Rosalind Advisors Inc. bought a new stake in shares of Chimerix during the 4th quarter valued at about $10,614,000. Boxer Capital Management LLC purchased a new stake in shares of Chimerix during the 4th quarter valued at about $7,169,000. Marshall Wace LLP lifted its stake in shares of Chimerix by 1,318.5% in the 4th quarter. Marshall Wace LLP now owns 2,213,940 shares of the biopharmaceutical company’s stock worth $7,705,000 after purchasing an additional 2,057,864 shares during the period. Finally, Peapod Lane Capital LLC bought a new position in shares of Chimerix in the 4th quarter worth approximately $2,626,000. Hedge funds and other institutional investors own 45.42% of the company’s stock.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.